GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (OTCPK:SZLSF) » Definitions » Gross Margin %

StageZero Life Sciences (StageZero Life Sciences) Gross Margin % : 22.55% (As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is StageZero Life Sciences Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. StageZero Life Sciences's Gross Profit for the three months ended in Sep. 2023 was $0.17 Mil. StageZero Life Sciences's Revenue for the three months ended in Sep. 2023 was $0.75 Mil. Therefore, StageZero Life Sciences's Gross Margin % for the quarter that ended in Sep. 2023 was 22.55%.


The historical rank and industry rank for StageZero Life Sciences's Gross Margin % or its related term are showing as below:

SZLSF' s Gross Margin % Range Over the Past 10 Years
Min: -691.8   Med: -25.03   Max: 95.16
Current: 0.25


During the past 13 years, the highest Gross Margin % of StageZero Life Sciences was 95.16%. The lowest was -691.80%. And the median was -25.03%.

SZLSF's Gross Margin % is ranked worse than
95.83% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: 45.595 vs SZLSF: 0.25

StageZero Life Sciences had a gross margin of 22.55% for the quarter that ended in Sep. 2023 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for StageZero Life Sciences was 0.00% per year.


StageZero Life Sciences Gross Margin % Historical Data

The historical data trend for StageZero Life Sciences's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences Gross Margin % Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -580.11 -691.37 16.76 23.22 -10.65

StageZero Life Sciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.27 -61.54 17.46 15.38 22.55

Competitive Comparison of StageZero Life Sciences's Gross Margin %

For the Diagnostics & Research subindustry, StageZero Life Sciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StageZero Life Sciences's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's Gross Margin % distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's Gross Margin % falls into.



StageZero Life Sciences Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

StageZero Life Sciences's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )=Gross Profit (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-0.4 / 3.795
=(Revenue - Cost of Goods Sold) / Revenue
=(3.795 - 4.199) / 3.795
=-10.65 %

StageZero Life Sciences's Gross Margin for the quarter that ended in Sep. 2023 is calculated as


Gross Margin % (Q: Sep. 2023 )=Gross Profit (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=0.2 / 0.745
=(Revenue - Cost of Goods Sold) / Revenue
=(0.745 - 0.577) / 0.745
=22.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


StageZero Life Sciences  (OTCPK:SZLSF) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

StageZero Life Sciences had a gross margin of 22.55% for the quarter that ended in Sep. 2023 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


StageZero Life Sciences Gross Margin % Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


StageZero Life Sciences (StageZero Life Sciences) Business Description

Traded in Other Exchanges
Address
70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.